Update on Immunotherapy for MBC: Immune Checkpoint Inhibitors - Metastatic Breast Cancer Trial Talk

Research News

Immune checkpoint inhibitors are a type of immunotherapy that uses the immune system’s natural ability to fight cancer. Immunotherapy is an active area of research for different MBC subtypes. Keytruda® and Jemperli® are currently approved immune checkpoint inhibitors for metastatic breast cancer.  Examples of immune checkpoint inhibitors under investigation for MBC include nivolumab, avelumab, and atezolizumab.

Click the links below for an introduction to immune checkpoint inhibitors and information about immune checkpoint inhibitors for MBC.

Introduction to Immune Checkpoint Inhibitors
Immune Checkpoint Inhibitors Approved for MBC
Immune Checkpoint Inhibitors in MBC Clinical Trials
Clinical Trials That Include Immune Checkpoint Inhibitors

Last Modified on April 6, 2022

Tags:

SEARCH OUR SITE

for past articles or specific information.